Eight papers, one terminated trial, and the slow regulatory tide that followed.

The record, in plain terms

The CJC-1295 research record fits on a short shelf. It begins with a 2005 rat study that identified how bonding the peptide to circulating albumin dramatically extends its activity. A 2006 human trial followed, dosing healthy adults and showing that a single injection raises growth hormone two- to tenfold for at least six days and raises IGF-1 — the downstream messenger — for up to eleven days. A companion paper the same year established that this sustained stimulation does not flatten the body's natural pulsatile GH rhythm.

There is also a Phase 2 trial in HIV-associated visceral fat that enrolled 192 people and stopped in 2006 after a participant death judged unrelated to the study drug. Primary efficacy data were never published. Nothing in the human file extends beyond short-term pharmacology.

This page reads those studies chronologically, with enough mechanism to make the pharmacokinetics make sense — and enough candor about what the file does not contain.

The receptor and the cascade

CJC-1295 is an agonist of the GHRH receptor (GHRHR), a class-B G-protein-coupled receptor expressed predominantly on somatotrophs of the anterior pituitary. Receptor binding activates a Gs / adenylyl cyclase / cAMP / PKA second-messenger cascade that drives GH gene transcription and pulsatile GH release ^[1]. Downstream of pituitary GH, hepatic IGF-1 production rises — and IGF-1, not GH itself, is the cleanest biomarker of axis activation across CJC-1295 studies ^[2][6].

Two features of the receptor architecture matter for the rest of this story. First, somatotrophs proliferate under sustained GHRH stimulation — Alba and colleagues documented somatotroph hyperplasia in CJC-1295-treated GHRH-knockout mice ^[5]. Second, GHRH activity shapes slow-wave sleep architecture; foundational neuroendocrine work in the 1990s established increased duration and intensity of NREM stage 3-4 sleep under IV GHRH infusion ^[13], which is the mechanistic reason GHRH-analog studies often discuss sleep as a candidate readout.

2005 — Jetté and the rat discovery paper

The first identification of CJC-1295 as a long-lasting GRF analog appeared in Endocrinology in 2005 ^[1]. Jetté and colleagues at ConjuChem characterized hGRF(1-29)-albumin bioconjugates that activated the GRF receptor on rat anterior pituitary. A single subcutaneous bolus produced a four-fold increase in GH area-under-curve over two hours and remained bioactive in circulation beyond seventy-two hours ^[1].

The paper established two facts the entire subsequent literature rests on. The maleimide-albumin bioconjugation does extend bioactivity by orders of magnitude over the parent peptide. And the receptor binding affinity of the four-substituted GRF(1-29) backbone is preserved despite the modifications ^[1][8].

2006 — Teichman and the only Phase 1 trial

Teichman and colleagues published the pivotal Phase 1 human PK study in JCEM in 2006 ^[2][3]. Healthy adults received single subcutaneous doses at 30, 60, 125, or 250 μg/kg, with weekly or biweekly multi-dose cohorts at 60 to 125 μg/kg ^[2].

The findings: mean plasma GH rose two- to ten-fold above baseline and remained elevated for at least six days ^[2]. Mean IGF-1 rose 1.5- to three-fold for nine to eleven days after a single dose ^[2]. Multi-dose cohorts sustained IGF-1 elevation through twenty-eight days ^[2]. Estimated plasma half-life across the single-dose cohorts ranged 5.8 to 8.1 days, attributed to the covalent albumin bioconjugation ^[3].

This is the human PK record. There is no Phase 1 expansion, no Phase 2 publication, and no Phase 3. Twenty years on, the Teichman cohort remains the published human dataset.

2006 — Ionescu and the pulsatility paper

A companion JCEM paper later in 2006 examined whether continuous CJC-1295 stimulation would flatten GH secretion into tonic output ^[4]. Ionescu and Frohman found it does not. Under single-dose CJC-1295, basal (trough) GH levels rose roughly 7.5-fold, mean GH ran about 46% above baseline, and pulse architecture was preserved ^[4].

This distinguishes CJC-1295 pharmacology from exogenous recombinant GH, where supraphysiological levels are sustained without the body's native pulsatile rhythm. Preserved pulsatility is one of the recurring rationales in the GHRH-analog literature for why a secretagogue is mechanistically different from direct GH administration — even if the long-term consequences of that distinction are not characterized for CJC-1295 specifically.

2006 — Alba and the GHRH-knockout mouse

The same year, Alba and colleagues published a GHRH-knockout mouse study in AJP-Endocrinology and Metabolism ^[5]. GHRH-KO mice grow short and lean by virtue of having no endogenous GHRH input to the pituitary. Once-daily subcutaneous CJC-1295 — 2 μg per injection (roughly 80 μg/kg in a 25-gram mouse) — normalized linear growth and body weight over five weeks. Less-frequent dosing at 48- or 72-hour intervals yielded partial restoration ^[5]. Treatment increased pituitary somatotroph proliferation and GH mRNA expression.

The mouse work is the cleanest demonstration in the file that CJC-1295 can restore a deficient GH axis to near-normal output. It also establishes that the multi-day plasma half-life translates to multi-day pharmacodynamic effect — a dose every 48 or 72 hours still produced measurable, partial restoration.

2009 — Sackmann-Sala and serum biomarkers

Sackmann-Sala and colleagues at Ohio University used 2D-electrophoresis proteomic analysis on serum from eleven healthy young men one week after a single CJC-1295 injection ^[6]. Five differentially expressed serum proteins emerged — apolipoprotein A1 and transthyretin isoforms decreased; β-hemoglobin, albumin C-terminal fragments, and immunoglobulin fragments increased. The immunoglobulin/albumin fragment spot correlated linearly with plasma IGF-1, offering candidate biomarkers of GHRH-analog exposure ^[6].

The paper is a small one, but it remains the most recent peer-reviewed human study to extend the original PK findings.

2006 — The Phase 2 termination

ConjuChem ran a Phase 2 randomized, double-blind, placebo-controlled trial of CJC-1295 in HIV-associated visceral adiposity — NCT00267527, n=192, weekly subcutaneous dosing ^[7]. The trial was terminated in October 2006 after a participant died from an acute coronary event approximately two hours after the eleventh weekly dose.

Independent review attributed the event to pre-existing undiagnosed coronary artery disease and judged it unrelated to study drug. The program was nevertheless halted, primary outcome data were never published in the peer-reviewed literature, and sponsor-funded development did not restart. The closely related FDA-approved GHRH analog tesamorelin went on to demonstrate a 15-20% reduction in visceral adipose tissue over six months in the same indication ^[15] — a benchmark efficacy profile for the class that CJC-1295's program was originally measured against, before it was closed.

Why GHRH analogs are paired with GHRPs

The widespread research-chemical and compounding-literature pairing of CJC-1295 with ipamorelin or other ghrelin-receptor agonists is grounded in Bowers and colleagues' 1990 JCEM paper showing that combined administration of GHRH and GHRP-6 produces a GH secretory response several-fold larger than either agent alone in healthy adults ^[9]. The two receptor systems — GHRHR on somatotrophs and GHS-R1a (the ghrelin receptor) — converge on GH release through different second-messenger pathways, producing a synergistic rather than additive output.

This is the mechanistic rationale for the pairing. It is not a published CJC-1295 + ipamorelin clinical trial result — there isn't one.

2024 — The regulatory closing

FDA's October 29, 2024 Pharmacy Compounding Advisory Committee reviewed CJC-1295 for potential inclusion on the Section 503A bulk drug substances list and did not recommend inclusion, citing immunogenicity, impurity-testing challenges, and adverse-event signals including increased heart rate and systemic vasodilatory reactions ^[14]. CJC-1295 was removed from FDA's Category 2 list effective September 27, 2024 ^[14]. A December 4, 2024 PCAC follow-up consolidated public comment and adverse-event review for the GH-secretagogue peptide class and reiterated insufficient evidence to support routine 503A access ^[17].

In parallel, WADA continues to list CJC-1295 under Section S2 — prohibited at all times for athletes subject to the Code ^[16]. Validated nano-LC Orbitrap mass spectrometry methods are in routine WADA-laboratory use for urine detection, addressing the analytical challenges of peptide instability and low urinary concentrations ^[12]. An earlier paper by Henninge and colleagues identified seized illicit material as CJC-1295 via LC-HRMS/MS sequence determination — confirming the compound's circulation in non-pharmaceutical supply channels ^[10].